Krystal Biotech, Inc. (KRYS)
| Market Cap | 7.93B |
| Revenue (ttm) | 389.13M |
| Net Income (ttm) | 204.83M |
| Shares Out | 29.44M |
| EPS (ttm) | 6.84 |
| PE Ratio | 39.37 |
| Forward PE | 34.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 142,583 |
| Open | 273.87 |
| Previous Close | 272.75 |
| Day's Range | 268.68 - 276.95 |
| 52-Week Range | 122.80 - 298.30 |
| Beta | 0.54 |
| Analysts | Strong Buy |
| Price Target | 297.60 (+10.52%) |
| Earnings Date | May 4, 2026 |
About KRYS
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey... [Read more]
Financial Performance
In 2025, Krystal Biotech's revenue was $389.13 million, an increase of 33.94% compared to the previous year's $290.52 million. Earnings were $204.83 million, an increase of 129.74%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for KRYS stock is "Strong Buy." The 12-month stock price target is $297.6, which is an increase of 10.52% from the latest price.
News
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026,...
Krystal Biotech Transcript: TD Cowen 46th Annual Health Care Conference
VYJUVEK's Q4 growth was driven by U.S. sales force expansion and a label update for at-home dosing, with ROW sales expected to lead 2026 growth. Pipeline programs in ocular and NK are advancing pivotal trials with increased dosing frequency, and the CF program is progressing through positive FDA discussions.
Krystal Biotech Earnings Call Transcript: Q4 2025
VYJUVEK delivered strong revenue growth in Q4 and 2025, driven by U.S. and accelerating ex-U.S. launches, with gross margins at 94% and robust net income. Pipeline progress, global expansion, and new FDA designations position the company for continued growth in 2026.
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Str...
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesda...
Krystal Biotech Transcript: 44th Annual J.P. Morgan Healthcare Conference
PTC exceeded 2025 revenue guidance, driven by a strong global launch of Sephience, which is showing broad uptake and high refill rates across PKU patient segments. The company expects continued Sephience momentum, international expansion, and progress in its Huntington’s and early-stage R&D programs, aiming for cash flow breakeven in 2026.
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 1...
Krystal Biotech Transcript: Study Update
Interim results from the Phase 1 CORAL-1 study of inhaled KB407 in cystic fibrosis showed successful, broad, and durable delivery of full-length CFTR to patient airways, with over 29% of cells transduced and a favorable safety profile. Plans are underway for a registrational repeat dosing study focused on functional lung improvement.
Krystal Biotech Transcript: Evercore ISI 8th Annual HealthCONx Conference
VYJUVEK continues global expansion with strong U.S. and Japan launches, robust pricing, and a solid financial position. Pipeline progress includes blinded ocular DEB and NK studies with clean safety profiles, and additional programs in CF, AATD, oncology, and Hailey-Hailey disease.
Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference
PITTSBURGH, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference o...
Krystal Biotech Earnings Call Transcript: Q3 2025
VYJUVEK revenue grew to $97.8M in Q3 2025, driven by U.S. and early European launches, with gross margin rising to 96%. Updated U.S. label, strong reimbursement trends, and pipeline progress support a positive outlook, while cash reserves exceed $864M.
FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin
The U.S. Food and Drug Administration (FDA) on Monday approved Krystal Biotech, Inc.'s KRYS label update for Vyjuvek (beremagene geperpavec-svdt).
Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NA...
Krystal Biotech Transcript: Cantor Global Healthcare Conference 2025
U.S. launch shows strong patient outcomes but follows a non-linear adoption curve, with sales force expansion and label updates aimed at improving reach and compliance. Multiple global launches and a robust pipeline, including ocular and neurotrophic keratitis programs, are progressing, with key regulatory milestones and data readouts expected over the next year.
Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer
PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, ...
Krystal Biotech Earnings Call Transcript: Q2 2025
Q2 2025 saw $96M in VYJUVEK revenue, 9% sequential growth, and $38.3M net income. U.S. growth was driven by patient restarts and Salesforce expansion, with European and Japanese launches set to boost future revenue. Over $820M in cash supports ongoing R&D and global expansion.
Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family
Krystal Biotech Transcript: Study Result
Phase 1 results for KB304 in decolletage wrinkles showed strong safety and efficacy, with 100% investigator-assessed improvement and high subject satisfaction. The therapy replenishes collagen III and elastin, addressing aging skin at its root, and is set for Phase 2 development in early 2026.
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE...
Krystal Biotech Transcript: Study Update
First patient dosed in the Phase I-II Emerald-1 study of KB801 for neurotrophic keratitis. Preclinical data show superior and sustained NGF delivery versus current therapy, supporting a twice-weekly dosing regimen. The study targets safety, efficacy, and potential for expedited development.
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PI...
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
Intra-patient, double-blind, multicenter, placebo-controlled study with crossover design Repeat administration under compassionate use was previously shown to be well tolerated and associated with ful...
Krystal Biotech Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025
Vyjuvek's U.S. launch is outperforming compliance expectations, with expanded sales efforts and a label change for self-administration underway. European launch is set for Q3, and pipeline programs in the eye and lung are advancing, supported by strong safety and regulatory momentum.
Krystal Biotech Transcript: BofA Securities 2025 Healthcare Conference
Vyjuvek's US launch remains strong despite Q1 revenue fluctuations, with European and Japanese launches set for later this year and pricing expected at 70-75% of US levels. Pipeline focus is on lung and eye therapies, with key data readouts and new trials planned in 2024-2025.